Interleukin 6 (IL6) was measured before and after treatment using a commercially available Quantikine enzyme linked immunosorbent assay in fifty seven patients with chronic hepatitis C treated with sofosbuvir and simeprevir for 3 months. RESULTS: The Mean values of IL6 level in responders and nonresponders were 272.96 and 230.5 pg/mL respectively. IL-6 levels decrease significantly after treatment in SVR. the best cut-off point for IL6 was 233 pg/mL with a sensitivity of 70%, a specificity of 75% and a positive predictive value of 97.2%, negative predictive value of 16.7%. CONCLUSION: Virological response during HCV therapy was associated with decrease in IL-6 level.
INTRODUCTION
HCV is a leading cause of chronic liver diseases, cirrhosis and hepatocellular carcinoma as well as the most common indication of liver transplantation in many countries [1] . Egypt has possibly the highest HCV prevalence in the world10-20% of the general population, Approximately 90% of Egyptian HCV isolates belong to a single subtype 4a which responds less successfully to interferon therapy than other genotypes [2] . The decision to treat patients with chronic hepatitis C depends on multiple parameters, including a precise assessment of the severity of liver disease and of its foreseeable outcome, the presence of absolute or relative contraindication to therapy and the patients willing to be treated [3] . Il-6 is apliotropic cytokine that plays a role in the acute phase response [4] . Il-6 is released from various cells, that is, Leukocytes, fibroblasts,
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after the end of treatment, Kidney function tests including: serum Creatinine level, Serum á-feto protein by ELISA and Measurement of interleukin 6 (IL-6) levels before and after treatment by commercially available Quantikine enzyme linked immunosorbent assay (ELISA) kit.
Statistical analysis
All data were collected, tabulated and statistically analyzed using STATA/SE version 11.2 for Windows (STATA corporation, College Station, Texas). Continuous data were expressed as the mean ± SD and range, and categorical data were expressed as a number and percentage. The Student t-test (t) was used to compare two groups of normally distributed data. While, Mann-Whitney test (z) was used to compare two groups of nonparametric data. The Wilcoxon signedrank test (z) was used to compare paired non-parametric data. Percent of categorical variables were compared using the Fisher's Exact Test.
Pearson correlation coefficient (r) and Spearman correlation coefficient (rho; ρ) were used to test for the correlation between estimated parameters.
Receiver Operating Characteristics (ROC) analysis was carried out to evaluate the diagnostic performance of IL-6 levels for response among patients. The best cutoff point and the corresponding sensitivity and specificity, Positive Predictive Value (PPV), Negative Predictive Value (NPV) and Area Under the Curve (AUC) were estimated.
After the calculation of each of the test statistics, the corresponding distribution tables were consulted to get the "P" (probability value). Statistical significance was accepted at p value <0.05 (S). A p value <0.001 was considered highly significant (HS) while a p value > 0.05 was considered non-significant.
RESULTS
This study was conducted on fifty seven patients with chronic hepatitis C and twenty six healthy people as control group attending out-patients clinic Shebien El-Kom Teaching Hospital from October 2015 to December 2015. From these cases, Fifty three patients (92.9%) were diagnosed as responders to treatment with sofosbuvir and simeprevir and four patients (7.02%) were non responders to treatment. after 3 months of the end of treatment 50 (87.72%) of responding patients develop sustained virological response (SVR) and the other 3 patients were missed. Table 1 show the Demographic and laboratory data between SVR and non-responders as The mean age for SVR was younger than nonresponders and the response to treatment tends to be more in males than in females. the Hemoglobin was significantly higher in SVR than non responders, The platelets was significantly higher in non responders than SVR. ALT, T. bil. and INR were significantly higher in non responders than SVR.
Baseline Il-6 levels were significantly high in patients than control group (Table 2, figure 1) .
As regard IL-6 levels before treatment were significantly higher in SVR than non-responders and After treatment IL-6 were significantly higher in non-responders than SVR (Table 3, figure 2 ).
No significance difference in IL-6 levels after treatment in nonresponders group and IL-6 levels decrease significantly after treatment in SVR (Table 4, figure 3 ).
There was negative correlation between IL-6 and platelets, white blood cells, alanine aminotransferase and INR and positive correlation with age, glucose, hemoglobin, aspertate aminotransferase, total bilirubin, albumin, creatinine, alpha feto protein, thyroid stimulating hormone and viral load however of non-significance (Table 5) .
endothelial cells and macrophages, in response to following systematic or local infection, tissue injury and inflammation [5] . As for the liver,Il-6 is produced mainly by kupffer cells [6] and induces the production of the acute phase proteins, C-reactive protein and haptoglobin [4] . Previous studies reported that serum Il-6 levels were increased, compared to healthy subjects, in patients with some liver diseases, such as chronic viral hepatitis due to HCV infection [6] . Previous results suggest that baseline levels of Il-6, as well as their decrease during treatment, are correlated to outcomes of HCV therapy in male patients. Further analyses of Il-6 may provide new strategies for difficult-to-treat CHC patients and prevention of hepatocarcinogenesis [7] . The aim of this work was to assess the possible role of IL-6 on response status of patients with HCV during treatment. Also we try to use IL-6 as a predictive factor for response in patients with chronic HCV.
PATIENTS AND METHODS
Subjectsthis study is a prospective study consists of 57 patients with chronic hepatitis C to be treated with sofosbuvir (400 mg once per day) and simeprevir (150 mg once per day) for 3 months devided into:
Group ( 
And further divided according to SVR (Group 3).
Group ( According to the national committee for control of viral hepatitis, Chronic HCV patient's candidate for combination therapy with sofosbuvir and simeprevir for 3 months and had the following inclusion criteria: Age from 18-70 years, HCV RNA positivity, Any Body Mass Index (BMI), Treatment naïve or treatment experienced and All fibrosis stages. Assessment of fibrosis is no more necessary. Performing liver biopsy or transient elastography (fibroscan) is not a pre-requisite; however, collection of such data is encouraged if available at the time of presentation. And Exclusion criteria are Direct serum bilirubin > 2 mg/dL, Serum albumin < 2.8 g/dL, International Normalization Ratio (INR) ≥ 1.7, Platelet count < 50000/mm 3 , Ascites or history of ascites, Hepatic encephalopathy or history of Hepatic encephalopathy, Hepatocellular Carcinoma (HCC), except 4 weeks after intervention aiming at cure with no evidence of activity by dynamic imaging (CT or MRI), Serum creatinine > 2.5 mg/dL. If creatinine is between 1.5 and 2.5 mg/dL, Glomerular Filtration Rate (GFR) should be calculated and should exceed 30 ml/min with favorable nephrological consultation, Extra-hepatic malignancy except after two years of disease-free interval and Pergnancy or inability to use effective contraception. Table 5 Correlations between IL-6 at baseline and other parameters. ROC for IL-6 for prediction of response show the best cut-off point for IL6 was 233 pg/mL with a sensitivity of 70%, a specificity of 75% and a positive predictive value of 97.2%, negative predictive value of 16.7% and the area under the curve was 0.6604 (Table 6 , figure 4 ).
Laboratory and molecular investigations
DISCUSSION
Egypt is enduring a large HCV disease burden, and is likely to be the most affected nation worldwide by this infection [8] .
There are a series of viral, host, and treatment characteristics that influence the likelihood of HCV treatment success and are useful when assessing the benefits and risks of therapy [9] . The introduction of direct-acting antiviral agents, in particular sofosbuvir (SOF), has revolutionized the treatment for chronic HCV. With SOF-based regimens, higher cure rates and shorter duration of treatment have been achieved. In early 2014, simeprevir (SIM) plus SOF, the first highly effective, interferon (IFN) sparing HCV treatment regimen, entered the clinical practice in the USA for the treatment of patients with HCV genotype 1 infection [10] . SMV is active against genotypes 1, 2, 4, 5 and 6. It is administered as a once-daily tablet orally and has demonstrated a favorable safety profile and limited drug drug interactions [11] . SIM/SOF combination therapy was more effective, better tolerated and associated with significantly fewer adverse events, compared with pegylated IFN-based regimens [12] . HCV infection can increase IL-6 production by altering the innate immune response by upregulating toll-like receptors (TLR4 and TLR2) in B cells, which will likely lead to an increased inflammatory response. The increased TLR4 and TLR2 expression is a result of increased transcription of the TLR4 and TLR2 genes and is mediated by the viral NS5A and core proteins, respectively [13] . This work aimed to study the association between IL-6 Levels and response to Sofosbuvir and Simeprevir in chronic hepatitis C virus patients.
In order to achieve this goal, this study was conducted on fifty seven patients with chronic hepatitis C and twenty six healthy people as control group attending Shebien El-Kom Teaching Hospital for treatment with sofosbuvir 400 mg once a day and simeprevir 150 mg once a day for 3 months from October 2015 to December 2015.
In this study, PCR was done for 57 patients with chronic HCV after 12 week of treatment with sofosbuvir and simprevir. 53 (92.98%) of patients develop response, and 4 (7.02%) of patients didn't develop response. after 3 months of the end of treatment 50 (87.72%) of responding patients develop sustained virological response (SVR) and the other 3 patients were missed.
El-Khayat et al [14] reported that The overall SVR rate was 95.7% (558 out of 583 patients). In total, SVR12 in naïve patients with mild fibrosis score (F1 and F2) In this study, Baseline IL-6 levels were significantly higher in patients than control group, this finding is in agreement with the result of El serafi et al [15] and Afzal et al [16] who reported that IL-6 levels were significantly higher in patients than control group.
In this study, responders who achieved SVR had significantly higher baseline IL-6 levels compared with those who did not before treatment and significantly lower after treatment.
This findings were in agreement with the results of El serafi et al [15] , who reported that CHC patients who achieved early virological response (EVR) had significantly higher IL-6 levels compared with those who did not, and IL-6 level greater than 2.15 pg/mL was significantly associated with EVR and could be considered as an independent predictor of EVR.
Also this finding were in agreement with the results of Faisal et al [17] and Nattermann et al [18] who reported that a higher level of IL-6 is significantly associated with SVR compared with a lower level. In contrast, Cotler et al [19] reported that there was no significant difference in basal IL-6 levels between the groups of responders and non-responders to IFN therapy.
A possible explanation of this finding that IL-6 level could modulate the response to treatment by activation of STAT3 by phosphorylation in hepatic stellate cells and by promoting their survival and proliferation. Furthermore, IFN-a activates STAT3, followed by induction of a wide variety of antiviral and proapoptotic genes that may contribute to the antiviral and antitumor activities of IFN-a in human livers [20] . STAT3 expression and activation are reduced in HCVinfected livers. The HCV core protein has been shown to prevent phosphorylation of STAT3, which has been associated with resistance of HCV to IFN therapy. IL-6 can overcome HCV core-induced inhibition of STAT3 activation and phosphorylation [21] . Studies by Mohamed et al [22] and Guzma ń-Fulgencio et al [23] showed a significant higher level of serum IL6 in non-responders compared to responders after Peg-IFN-α and RBV therapy. They explained this correlation by that IL6 promotes suppressor of cytokine signaling 3 (SOCS3) expressions which suppress the JAK-STAT pathway and inhibits the formation of interferon-stimulated gene [24] , therefore, suppression of interferon-stimulated gene through activating IL6/SOCS3 signal results in resistance to IFN therapy.
In this study, there was negative correlation between IL-6 and platelets, white blood cells, alanine aminotransferase and INR and positive correlation with age, glucose, hemoglobin, aspertate aminotransferase, total bilirubin, albumin, creatinine, alpha feto protein, thyroid stimulating hormone and viral load however of nonsignificance.
Mohamed et al [22] reported that There was a negative correlation between the serum levels of IL6 and AST and also between serum levels of TNFRI and ALT may indicate that the level of both marker reflect liver injury despite low levels of liver enzymes.
In this study, ROC for IL-6 for prediction of response show the best cut-off point for IL6 was 233 pg/ml with a sensitivity of 70%, a specificity of 75% and a positive predictive value of 97.2%, negative predictive value of 16.7% and the area under the curve was 0.6604. El serafi et al [15] , reported that IL-6 level greater than 2.15 pg/ml was significantly associated with response and could be considered as an independent predictor of response.
